

Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/PA02AE7248DEN.html>

Date: April 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: PA02AE7248DEN

Abstracts

Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that is involved in the development and commercialization of recombinant therapeutic proteins. The company's marketed product, Eleyso (taliglucerase alfa), is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease, cystic fibrosis and NETs related diseases. The company develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology, ProCellEx plant cell-based protein expression system. It allows the company to rapidly develop a protein for clinical testing, compared to other protein platforms. Protalix is headquartered in Carmiel, Israel.

Protalix BioTherapeutics Inc Key Recent Developments

Mar 30,2021: Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results

Mar 22,2021: Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021

Dec 30,2020: Protalix BioTherapeutics issues 2020 letter to shareholders

Oct 29,2020: Protalix BioTherapeutics reports third quarter 2020 financial results and provides business update

Oct 29,2020: Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Protalix BioTherapeutics Inc - Key Facts
Protalix BioTherapeutics Inc - Key Employees
Protalix BioTherapeutics Inc - Key Employee Biographies
Protalix BioTherapeutics Inc - Major Products and Services
Protalix BioTherapeutics Inc - History
Protalix BioTherapeutics Inc - Company Statement
Protalix BioTherapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Protalix BioTherapeutics Inc - Business Description
R&D Overview
Protalix BioTherapeutics Inc - Corporate Strategy
Protalix BioTherapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Protalix BioTherapeutics Inc - Strengths
Protalix BioTherapeutics Inc - Weaknesses
Protalix BioTherapeutics Inc - Opportunities
Protalix BioTherapeutics Inc - Threats
Protalix BioTherapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Protalix BioTherapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 30, 2021: Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results

Mar 22, 2021: Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021

Dec 30, 2020: Protalix BioTherapeutics issues 2020 letter to shareholders

Oct 29, 2020: Protalix BioTherapeutics reports third quarter 2020 financial results and provides business update

Oct 29, 2020: Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October

Sep 08, 2020: Protalix BioTherapeutics regains compliance with NYSE American Continued Listing Standards

Aug 10, 2020: Protalix BioTherapeutics reports second quarter 2020 financial results and provides business update

Jun 08, 2020: Protalix BioTherapeutics appoints Yael Hayon, Ph.D. as its new Vice President, Research and Development

Jun 01, 2020: Protalix BioTherapeutics reports first quarter 2020 financial results and business update

Mar 16, 2020: Protalix Biotherapeutics announces feasibility study with Kirin Holdings on the production of a novel complex protein

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Protalix BioTherapeutics Inc, Key Facts
Protalix BioTherapeutics Inc, Key Employees
Protalix BioTherapeutics Inc, Key Employee Biographies
Protalix BioTherapeutics Inc, Major Products and Services
Protalix BioTherapeutics Inc, History
Protalix BioTherapeutics Inc, Subsidiaries
Protalix BioTherapeutics Inc, Key Competitors
Protalix BioTherapeutics Inc, Ratios based on current share price
Protalix BioTherapeutics Inc, Annual Ratios
Protalix BioTherapeutics Inc, Annual Ratios (Cont...1)
Protalix BioTherapeutics Inc, Interim Ratios
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Protalix BioTherapeutics Inc, Performance Chart (2016 - 2020)

Protalix BioTherapeutics Inc, Ratio Charts

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/PA02AE7248DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PA02AE7248DEN.html>